Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia.
Several features are characteristic for hairy cell leukemia (HCL). Among those are pancytopenia, bone marrow fibrosis, and the appearance of a defined tumor cell phenotype in peripheral blood (PB), bone marrow (BM), and spleen. Hairy cells (HC) coexpress antigens specific for B lymphocytes and monocytes/macrophages and thus the malignant cell does not seem to be restricted to a defined lineage. When serum or bone marrow aspirate was screened by enzyme-linked immunosorbent assay (ELISA) for basic fibroblast growth factor (bFGF), specimen derived from HCL (serum: mean value, 29 pg/mL; BM aspirate: mean value, 641 pg/mL) contained significantly higher levels than those from healthy subjects. To study whether peripheral blood mononuclear cells (PBMC) derived from patients suffering from HCL and healthy donors (HD) were capable of producing bFGF, culture supernatant (conditioned medium, [CM]) was tested for the presence of this cytokine. While bFGF was not detectable in cell cultures from HD, HCL-derived CM contained relatively high levels of bFGF. CM was successfully used for stimulation of mesenchymal cell proliferation, which could be inhibited by a neutralizing anti-bFGF antibody. Cellular activation by pokeweed mitogen (PWM) or the combination of 12-o-tetradecanoyl-phorbol-13-acetate (TPA) plus calcium ionophore (Ca-Ip) led to an enhanced mRNA expression. Results of Western blot experiments showed that HC synthesize at least three isoforms (approximately 18, 23, and 25 kD), but only the 23-kD isoform is exported. To assess the nature of the producer cell, double immunofluorescence analysis using a bFGF-specific and an anti-CD11c monoclonal antibody (MoAb) was undertaken. The majority of cells scoring positive for CD11c were also reactive with the anti-bFGF MoAb. Furthermore, enrichment of CD19/CD11c-positive cells correlated with enhanced bFGF levels, thereby supporting the argument for HC being the producer cells of bFGF. A biological function of bFGF in HCL might be mediation of chemoresistance, as 2-chlorodeoxyadenosine (2-CdA)-induced inhibition of cell proliferation can be reversed by bFGF. Endogenous bFGF production by HC is not affected by this purine analogue and 2-CdA-induced apoptosis is diminished in bFGF-producing HC as compared with normal PBMC. Therefore, bFGF expression by HC might be important for resistance to chemotherapy and survival of the malignant cells.
Ludwig Boltzmann Institute for Cytokine Research and the Department of Internal Medicine I, Division of Hematology, University of Vienna Medical School, Vienna, Austria.
G
G
Gruber
J D
JD
Schwarzmeier
M
M
Shehata
M
M
Hilgarth
R
R
Berger
D000368:Aged; D000369:Aged, 80 and over; D018941:Antigens, CD19; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis; D017338:Cladribine / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000096:biosynthesis*; D006801:Humans; D016167:Integrin alphaXbeta2; D007943:Leukemia, Hairy Cell / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism*; D008297:Male; D008875:Middle Aged
D018941:Antigens, CD19; D000970:Antineoplastic Agents; D016167:Integrin alphaXbeta2; D016222:Fibroblast Growth Factor 2; D017338:Cladribine